BridgeBio Pharma (BBIO) Non Operating Income (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Non Operating Income data on file, last reported at -$60.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 7.11% year-over-year to -$60.6 million; the trailing twelve-month figure through Mar 2026 stood at -$204.5 million (down 1027.4% YoY), and the FY2025 full-year result was -$209.1 million, down 511.77% from the prior year.
• Non Operating Income slipped to -$60.6 million in Q1 2026, from -$55.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $100.0 million in Q2 2024 to a low of -$65.2 million in Q1 2025.
• A 5-year average of -$14.0 million and a median of -$21.8 million in 2023 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 1063.11% in 2022, while the deepest fall reached 672.83% in 2022.
• Tracing BBIO's Non Operating Income over 5 years: stood at -$11.3 million in 2022, then soared by 162.52% to $7.1 million in 2023, then tumbled by 667.28% to -$40.2 million in 2024, then tumbled by 37.27% to -$55.2 million in 2025, then dropped by 9.79% to -$60.6 million in 2026.
• Business Quant data shows BBIO's Non Operating Income at -$60.6 million in Q1 2026, -$55.2 million in Q4 2025, and -$41.3 million in Q3 2025.